• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

AbbVie's Rinvoq conquers Regeneron and Sanofi's Dupixent in eczema trial—again

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 26, 2024 at 11:42: AM
via For the second time in four years, AbbVie’s Rinvoq (upadacitinib) has shown superior efficacy to Regeneron and Sanofi’s powerhouse Dupixent (dupilumab) in a head-to-head study in patients with atopic dermatitis (AD).

article source
 

<



Similar threads

cafead
AbbVie&#039;s Rinvoq passes midstage test in systemic lupus erythematosus, heads into phase 3
Replies
0
Views
141
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AbbVie&#039;s Rinvoq scores its 7th FDA nod, this one for Crohn&#039;s disease
Replies
0
Views
225
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AbbVie&#039;s red-hot Rinvoq scores fourth FDA approval in five months
Replies
0
Views
190
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Ahead of Humira&#039;s patent cliff, AbbVie&#039;s Rinvoq notches third new use in 4 months
Replies
0
Views
207
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AbbVie&#039;s Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an...
Replies
0
Views
270
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote